Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2015-02-05 Board/Management Inform…
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The text specifically mentions Item 5.02, which relates to the departure of officers and directors and changes in compensatory arrangements. It details the re-pricing of stock options for officers, directors, and employees, and the departure of a Chief Operating and Legal Officer. There is no indication of financial statements or earnings data, so it is not an earnings release or financial report. The content fits the category of Board/Management Information (MANG) because it announces changes in management and related compensatory actions. The document length is 3235 characters, which is typical for an 8-K filing of this nature and not a brief announcement or a full report. Therefore, the classification is MANG with high confidence.
2015-02-05 English
FORM 10-K/A
Annual Report FY 2014
2015-01-29 English
FORM 10-K
Annual Report FY 2014
2015-01-29 English
PRIMARY DOCUMENT
Director's Dealing
2015-01-06 English
PRIMARY DOCUMENT
Director's Dealing
2015-01-06 English
PRIMARY DOCUMENT
Director's Dealing
2015-01-06 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.